Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Irving Investors
AddedFeb 11, 2024
UpdatedJun 28, 2026
Irving Investors

Irving Investors

Operating

Irving Investors: A tech-focused fund investing in disruptive, high-growth opportunities.

Location
New York City, NY, US
Founded
2009
Firm
Compare
Portfolio
Employees
Website

Investments

Turo
Turo

Total Raised

$502.6M

Rounds

14

Secondary MarketAugust 2023
Attentive
Attentive
Debt

Total Raised

$863M

Rounds

8

DebtAugust 2023
OneTrust
OneTrust

Total Raised

$1.1B

Rounds

7

Secondary MarketAugust 2023
Databricks
Databricks

Total Raised

$29.2B

Rounds

14

Secondary MarketJuly 2023
Icertis
Icertis

Total Raised

$516M

Rounds

11

Secondary MarketMarch 2023
Snyk
Snyk

Total Raised

$1.2B

Rounds

13

Series G$196.5MDecember 2022
Chainalysis
Chainalysis

Total Raised

$536.6M

Rounds

11

Secondary MarketOctober 2022
Klaviyo
Klaviyo
Public

Total Raised

$1.1B

Rounds

10

Secondary MarketSeptember 2022
Metagenomi
Metagenomi

Total Raised

$457M

Rounds

7

Series B$175MJanuary 2022
Checkr
Checkr
Series E

Total Raised

$679.1M

Rounds

8

Secondary MarketJanuary 2022
Arctic Wolf Networks
Arctic Wolf Networks

Total Raised

$899.2M

Rounds

9

Secondary MarketJanuary 2022
Leap
Leap

Total Raised

$99.8M

Rounds

8

Series B$50MDecember 2021
Bombas
Bombas

Total Raised

$150M

Rounds

4

Secondary MarketDecember 2021
Shoreline Biosciences
Shoreline Biosciences

Total Raised

$186M

Rounds

3

Series B$140MNovember 2021
InterVenn Biosciences
InterVenn Biosciences

Total Raised

$278.1M

Rounds

5

Series C$201MAugust 2021
Genomatica
Genomatica

Total Raised

$340.3M

Rounds

10

Series C$118MJuly 2021
Cybereason
Cybereason

Total Raised

$850.6M

Rounds

9

Series F$275MJuly 2021
Biotheryx
Biotheryx
Public

Total Raised

$134.7M

Rounds

6

Series E$92MMay 2021
Crossover Health
Crossover Health

Total Raised

$281.5M

Rounds

4

Series D$168MMarch 2021
Absci
Absci
Public

Total Raised

$237.9M

Rounds

11

Series Unknown$125MMarch 2021
eGenesis
eGenesis

Total Raised

$265M

Rounds

4

Series C$125MMarch 2021
Model Medicines
Model Medicines

Total Raised

$4.1M

Rounds

2

Seed$4.1MFebruary 2021
Goldfinch Bio
Goldfinch Bio
Public

Total Raised

$210M

Rounds

3

Series B$100MJune 2020
SentinelOne
SentinelOne
Public

Total Raised

$696.5M

Rounds

10

Series E$200MFebruary 2020
Rubrik
Rubrik

Total Raised

$554.3M

Rounds

10

Secondary MarketDecember 2019